Belite Bio

Business news, market intelligence, and global industry analysis.

The Latest

Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Belite Bio wins UK MHRA nod to file conditional marketing application for tinlarebant in Stargardt disease

Find out how Belite Bio gained UK MHRA backing to file a conditional marketing application for tinlarebant, advancing the first potential therapy for Stargardt disease.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

November 3, 2025